Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Кистозный фиброз (муковисцидоз)

Список литературы

  1. Муковисцидоз. Под редакцией Н.И. Капранова, Н.Ю. Каширской. МЕДПРАКТИКА-М.: 2014. 672 с.
  2. Национальный консенсус «Муковисцидоз: определение, диагностические критерии, терапия» Под редакцией Е.И. Кондратьевой, Н.Ю. Каширской, Н.И. Капранова. Москва, ООО «Компания БОРГЕС». 2016, 205 с. https://mukoviscidoz.org/doc/konsensus/CF_consensus_2017.pdf
  3. De Boeck K. Cystic fibrosis in the year 2020: disease with a new face. Acta Paediatr. 2020; 109(5): 893– 899. DOI: 10.1111/apa.15155
  4. Lopes-Pacheco M. CFTR modulators: Shedding light on precision medicine for cystic fibrosis. Front. Pharmacol. 2016; 7: 275. DOI: 10.3389/fphar.2016.00275.]
  5. Регистр больных муковисцидозом в Российской Федерации. 2019 год. / Под редакцией А.Ю. Воронковой, Е.Л. Амелиной, Н.Ю. Каширской, Е.И. Кондратьевой, С.А. Красовского, М.А. Стариновой, Н.И. Капранова. – М.: ИД «МЕДПРАКТИКА-М», 2021,  68 с. https://mukoviscidoz.org/doc/registr/10472_block_Registre_2017%20site.pdf   4
  6. P.J. Mogayzel, E.T. Naureckas, K.A. Robinson Cystic Fibrosis Pulmonary Guidelines. Am. J. Respir. Crit. Care Med. 2013; 187: 680–689.
  7. Шагинян И.А., Капранов Н.И., Чернуха М.Ю., Г.В. Алексеева, С.Ю. Семыкин, Аветисян Л.Р., Н.Ю. Каширская, Н.В. Пивкина, Г.А. Данилина, А.Б. Батов, Г.П. Бусуек. Микробный пейзаж нижних дыхательных путей у различных возрастных групп детей, больных муковисцидозом. ЖМЭИ 2010; № 1: с. 15-20
  8. Чернуха М.Ю., Шагинян И.А., Капранов Н.И., Алексеева Г.В., Каширская Н.Ю., Аветисян Л.Р., Семыкин С.Ю., Данилина Г.А., Поликарпова С.В., Пивкина Н.В. Персистенция Burkholderia cepacia у больных муковисцидозом. ЖМЭИ 2012; № 4: с. 93-98
  9. Demco C.A., Stern R.C., Doershuk C.F. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr. Pulmonol 1998; 25(5):304-8.;  Liu L., Coenye T., Burns J.L., Whitby P.W., Stull T.L., LiPuma J.J. Ribosomal \DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylooxidans recovered from sputum samples from cystic fibrosis patients. J. Clin. Microdiol 2002; 40(4):1210-3.
  10. Аветисян Л.Р., Медведева О.С., Чернуха М.Ю., Шагинян И.А., Тихомиров Е.Е., Прилипов А.Г., Русакова Е.В., Хачиян М.М., Кондратьева Е.И., Воронкова А.Ю., Шерман В.Д., Красовский С.А., Афанасьева М.В. Эпидемиологические и микробиологические особенности хронической инфекции легких у больных муковисцидозом вызванной  Staphylococcus aureus. Педиатрия. Журнал им. Г.Н. Сперанского. 2020. Т. 99. № 2. С. 102-11110.24110/0031-403X-2020-99-2-102-111
  11. Сиянова Е.А., Чернуха М.Ю.,  Аветисян Л.Р., Шагинян И.А, А.Г. Прилипов, Е.И. Кондратьева, Припутневич Т.В., Гордеев А.В., Каширская Н.Ю,  Н.И. Капранов, И.А. Ильенкова, Красовский С.А..Воронкова Л.Ю., Амелина Е.Л., М.В. Усачева  Мониторинг хронической инфекции легких у больных муковисцидозом, вызванной бактериями Pseudomonas аeruginosa. Педиатрия. Журнал им. Г.Н. Сперанского: Науч. журн./  Изд-во: ООО «Педиатрия» Москва, Том 97, №2, 2018 C.77- 86.
  12. LiuJ.C. etal. What is the clinical significance of filamentous fungi positive sputum cultures in patients with cystic fibrosis? Journal of Cystic Fibrosis 12 (2013) 187–193
  13. Aaron SD, Vandemheen KL, Freitag A, Pedder L, Cameron W, Lavoie A, et al. Treatment of Aspergillus fumigates in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoSOne 2012; 7:e36077.
  14. Eickmeier O., Hector A., Singh A., Hart D. Fungi in Cystic Fibrosis: Recent Findings and Unresolved Questions. CurrentFungalInfectionReports •2014
  15. Климко Н.Н. Микозы: диагностика и лечение Руководство для врачей. — 3-е изд., перераб. и доп. — М.:Фармтек, 2017. — 272 с.
  16. PinetM, CarrereJ., CimonB., etal. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis—a review. MedicalMycologyJune 2009, 47 (SpecialIssue), 387-397
  17. Denning D.W., Cadranel J., Beigelman-Aubry C., etal. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016; 47: 45–68
  18. Кosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax 2015; 70: 270–277
  19. Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, Bareil C, Bilton D, Castellani C, Cuppens H, Cutting GR, Drevínek P, Farrell P, Elborn JS, Jarvi K, Kerem B, Kerem E, Knowles M, Macek M Jr, Munck A, Radojkovic D, Seia M, Sheppard DN, Southern KW, Stuhrmann M, Tullis E, Zielenski J, Pignatti PF, Ferec C. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011; 10(2): 86–102.
  20. De Boeck K, Wilschanski M, Castellani C,Taylor C , Cuppens H,  Dodge J, Sinaasappel M. Cystic fibrosis: terminology and diagnostic algorithms. Thorax. 2006;61:627–635.
  21. Burke M.S., Ragi J.M., Karamanoukian H.L. et al. New strategies in thenon-operative management of meconium ileus. J. Pediat. Surg. 2002; 37: 760—764
  22. CastellaniC, DuffAJA, BellSC, HeijermanHGM, MunckA, RatjenF, Sermet-GaudelusI, SouthernKW, BarbenJ, FlumePA, Hodková P, KashirskayaN, KirszenbaumMN, MadgeS, OxleyH, PlantB, SchwarzenbergSJ, SmythAR, TaccettiG, Wagner TOF, Wolfe SP, Drevinek P. ECFS best practice guidelines: the 2018 revision. JCystFibros. 2018 Mar;17(2):153-17
  23. Кондратьева Е.И., Шерман В. Д., Амелина Е.Л., Воронкова А.Ю., Красовский С.А., Каширская Н.Ю., Петрова Н.В., Черняк А. В., Капранов Н. И., Никонова В.С., Шабалова Л.А.Клинико-генетическая характеристика и исходы мекониевого илеуса при муковисцидозе  Российский вестник перинаталогии и педиатрии, 2016, 61:6; 77-81 DOI 10.21508/1027-4065-2016-6-77-81
  24. Debray D, Narkewicz MR, Bodewes FA, et al. Cystic Fibrosis– related Liver Disease: Research Challenges and Future Perspectives. J Pediatr Gastroenterol Nutr. 2017;65:443-448
  25. Ciucă IM, Pop L, Tămaş L, et al. Cystic fibrosis liver disease-from diagnosis to risk factors. RomJMorpholEmbryol. 2014;55:91-95
  26. Klotter V, Gunchick C, Siemers E, et al. Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study. PloSone. 2017;12:e0178784
  27. Terliesner N, Vogel M, Steighardt A, Gausche R, Henn C, Hentschel J, Kapellen T, Klamt S, Gebhardt J, Kiess W, Prenzel F. Cystic-fibrosis related-diabetes (CFRD) is preceded by and associated with growth failure and deteriorating lung function. JPediatrEndocrinolMetab. 2017;34-51.doi: 10.1002/ppul.21127
  28. Edenborough FP. Women with cystic fibrosis and their potential for reproduction. Thorax 2001;Aug 56(8):649–55
  29. Амелина Е.Л., Красовский С.А., Шугинин И.О. Муковисцидоз и беременность: клинико-генетические, функциональные и микробиологические характеристики пациенток. Педиатрия. Журнал им. Г.Н. Сперанского. 2014. Т. 93. № 4. С. 38-43
  30. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd. Cystic fibrosis foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008; 153 (2): 4–14.
  31. King S.L., Topliss D.J., Kotsimbos T. et al. Reduced bone density in cystic fibrosis: ∆F508 mutation is an independent risk factor. Eur. Respir. J. 2005; 25: 54-61.
  32. Симанова Т. В. Клинико-генетические особенности и костный метаболизм у больных муковисцидозом: автореф…. канд. мед.наук. М., 2009-28с.
  33. Красовский С.А. Остеопороз у взрослых больных муковисцидозом: автореф. дис… канд. мед.наук. М., 2012
  34. Горинова Ю.В. Остеопения при хронических болезнях легких у детей: автореф. дис. …канд. мед.наук. М., 2005
  35. Соболенкова В.С. Системный анализ в ранней диагностике и лечении остеопенического синдрома при муковисцидозе: автореф. дис….канд. мед.наук.  Тула, 2009
  36. ArisR.M., MerkelP.A., BachrachL.K., etal. Consensus statement: Guide to bone health and disease in cystic fibrosis. J.Clin.Endocrinol.Metab. 2005; 90(3): 1888-1896
  37. Ашерова И.К., 2006, Капранов Н.И., Капустина Т.Ю.Состояние минеральной плотности костной ткани у пациентов с муковисцидозом Педиатрия. 2008.-N 5.-С.36-41
  38. A. R. Smyth, S.C. Bell , S.Bojcin , M.Bryon, A. Duff, P.A. Flume European Cystic Fibrosis Society Standards of Care: Best Practice guidelines J Cyst Fibrosis. 2014. v.13. S23–S42.
  39. StevensD.A., MossR.B., KurupV.P., etal. Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003; 37 Suppl 3:S225–64
  40. Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest 1999 116: 639–646
  41. Mastella G., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis: a European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. 2000 Sep;16(3):464-71
  42. Zolin A., Orenti A., Naehrlich L., van Rens J. Et al. ECFSPR European Cystic Fibrosis Society Patient Registry Annual data report (year 2017) version 1.2019. Available at www.ecfs.eu/ecfs-patient-registry
  43. Leung DH, Narkewicz MR. Cystic Fibrosis-related cirrhosis. J Cyst Fibros. 2017 Nov;16 Suppl 2:S50-S61
  44. Mayer-Hamblett N, Kloster M, Ramsey BW, et al. Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials. ContempClin Trials. 2013;34:232-238.
  45. Akata D, Akhan O. Liver manifestations of cystic fibrosis. Eur J Radiol. 2007;61:11-17
  46. Williams SM, Goodman R, Thomson A, et al. Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9-year review. ClinRadiol. 2002;57:365-370, Tanner MS, Taylor CJ. Liver disease in cystic fibrosis. Arch Rev Clin Med 2018; Vol 5 (No 4) Published by: Mashhad University of Medical Sciences (http://rcm.mums.ac.ir) 149 Kianifar HR et al. Dis Child. 1995;72:281-284
  47. Mueller-Abt PR, Frawley KJ, Greer RM, et al. Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease. J CystFibros. 2008;7:215-221
  48. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42 Suppl(1):S100-7. Epub 2004 Dec 24
  49. Brunt, M.E. Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond. / M.E. Brunt // Hepatology. – 2000. – Vol. 31 (1).  – Р. 241-246
  50. Moran A, Brunzell C, Cohen RC. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. DiabetesCare. 2010;33(12):2697-708. doi: 10.2337/dc10-1768
  51. Gordon C M, Leonard M B, Zemel B S. 2013 Pediatric Position Development Conference: Executive Summary and Reflections. Journal of Clinical Densitometry: Assessment & Management of Musculoskeletal Health; 2014; vol. 17, № 2, 219-224
  52. Southern KW, Mérelle MM, Dankert-Roelse JE, Nagelkerke AD. Newborn screening for cystic fibrosis.Cochrane Database Syst Rev. 2009 Jan 21;(1):CD001402
  53. Шерман В.Д., Кондратьева Е.И., Воронкова А.Ю., Каширская Н.Ю., Шабалова Л.А., Никонова В.С., Жекайте Е.К., Куцев С.И. Влияние неонатального скрининга на течение муковисцидоза на примере группы пациентов московского региона. Медицинский Совет. 2017;(18):124-128. https://doi.org/10.21518/2079-701X-2017-18-124-128
  54. Шерман В.Д., Капранов Н.И., Каширская Н.Ю., Кондратьева Е.И. Роль неонатального скрининга в оптимизации медицинской помощи больным муковисцидозом в РФ. Медицинская генетика. 2013; 11: 24–29.
  55. Collie JT, Massie RJ, Jones OA, LeGrys VA, Greaves RF. Sixty-five years since the New York heat wave: advances in sweat testing for cystic fibrosis. Pediatr Pulmonol. 2014 Feb;49(2):106-17
  56. Mattar A. C. V. et al. Sweat conductivity: an accurate diagnostic test for cystic fibrosis? Journal of Cystic Fibrosis.2014;13(5):528-533
  57. Hug M.J., Tümmler B. Intestinal current measurements to diagnose cystic fibrosis J Cyst Fibros 2004 ;  3 (Suppl. 2) : 157-158.
  58. Derichs N., Sanz J., Von Kanel T., Stolpe C., Zapf A., Tümmler B., and al. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data Thorax 2010 ;  65 : 594-599
  59. Sosnay P.R., White T.B, Farrell P.M., Ren C.L., Derichs N., Howenstine M.S., Nick J.A., De Boeck K. Diagnosis of Cystic Fibrosis in Nonscreened Populations. J Pediatr 2017;181S:S52-7). http://dx.doi.org10.1016/j.jpeds.2016.09.068
  60. http://www.genet.sickkids.on.ca/cftr,  http://seqdb. med-gen.ru, https://cftr2.org
  61. S. Richards, N. Aziz, S. Bale, D. Bick, S. Das, J. Gastier-Foster, W. W. Grody, M. Hegde, E. Lyon, E. Spector, K. Voelkerding, H.L. Rehm, the ACMG Laboratory Quality Assurance Committee Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Genetics in medicine. Volume 17.| Number 5. 2015. P.405-424. doi:10.1038/gim.2015.30., https://www.sciencedirect.com/science/article/pii/S1569199318300298
  62. Turck D, Braegger CP, Colombo C, Declercq D, Morton A, Pancheva R, Robberecht E, Stern M, Strandvik B, Wolfe S, Schneider SM, Wilschanski M ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 2016 Jun;35(3):557-77
  63. https://www.nice.org.uk/guidance/ng78/resources/cystic-fibrosis-diagnosis-and-management-pdf-1837640946373
  64. Goss CH, Mayer-Hamblett N, Kronmal RA, Williams J, Ramsey BW. Laboratory parameter profiles among patients with cystic fibrosis J Cyst Fibros. 2007 Apr;6(2):117-23
  65. Nazareth D, Walshaw M. A review of renal disease in cystic fibrosis. J Cyst Fibros. 2013 Jul;12(4):309-17
  66. D’SouzaHA, BaronEJ. BBL CHROMagar Staph aureus is superior to mannitol salt for detection of Staphylococcus aureus in complex mixed infections. Am J Clin Pathol 2005; 123: 806-808
  67. Рекомендации «Определение чувствительности микроорганизмов к антимикробным препаратам», 2021 г. https://www.antibiotic.ru/files/321/clrec-dsma2018.pdf
  68. Страчунский Л.С (ред.) Методические рекомендации для микробиологов «Выделение, идентификация и определение чувствительности к антибиотикам Haemophilus influenzae». КММАХ; 2000;2(2):93-109
  69. Wright RM, Moore JE, Shaw A, Dunbar K, Dodd M, Webb K, et al. Improved cultural detection of Burkholderia cepacia from sputum in patients with cystic fibrosis. JClinPathol 2001;54:803-5
  70. UK Standards for Microbiology Investigations Identification of Pseudomonas species and other Non Glucose Fermenters Bacteriology – Identification. ID 17. Issue no: 3. Issue date: 13.04.15. Page: 2-41 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/422699/ID_17i3.pdf
  71. Manual of clinical microbiology — 11th edition / editors in chief, JamesH. Jorgensen, MichaelA. Pfaller; volume editors, KarenC. Carroll [and 4 others]. – 2015 p.774
  72. Gilligan, P. H., D. L. Kiska, and M. D. Appleman. 2006. Cumitech 43, Cystic Fibrosis Microbiology. Coordinating ed., M. D. Appleman. ASM Press, Washington, D.C. с. 10-19
  73. Burns JL, Saiman L, Whittier S, Krzewinski J, Liu Z, Larone D, Marshall SA, Jones RN. 2001. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis 39:257–260
  74. Marley EF, Mohla C, Campos JM. 1995. Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 33:3191–3193
  75. Di Bonaventura G, Ricci E, Della Loggia N, Catamo G, Piccolomini R. 1998. Evaluation of the E test for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from patients with long-term bladder catheterization. J Clin Microbiol 36:824–826
  76. Zebouh M, Thomas C, Honderlick P, Lemee L, Segonds C, Wallet F, Husson M-O. Direct antimicrobial susceptibility testing method for analysis of sputum collected from patients with cystic fibrosis. J Cystic Fibrosis 2008; 7: 238-243
  77. Morosini MI, Garcia-Castillo M, Loza E, Perez-Vazquez M, Baquero F, Canton R. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to tobramycin in cystic fibrosis patients: use of highrange Etest strips. J Clin Microbiol 2005; 43: 4480-4485
  78. Poole K, Srikumar R. 2001. Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr Top Med Chem 1:59–71
  79. Hogardt M, Ulrich J, Riehn-Kopp H, Tummler B. EuroCare quality assessment of diagnostic microbiology of cystic fibrosis isolates. J Clin Microbiol 2009; 47: 3435-3438
  80. Руководство по микробиологической диагностике инфекций дыхательных путей у пациентов с муковисцидозом / С. В. Поликарпова, С. В. Жилина, О. В. Кондратенко [и др.]. – Тверь, 2019. –128 с.
  81. https://eucast.org/ast_of_bacteria/guidance_documents/ EuropeanCommittee on Antimicrobial Susceptibility Testing, Европейский комитет по определению чувствительности к антимикробным препаратам
  82. https://clsi.org/ Clinical and Laboratory Standards Institute, Институт клинических и лабораторных стандартов
  83. Приказ Минздрава РФ от 21.03.2003 № 109 «О совершенствовании противотуберкулезных мероприятий в Российской Федерации». (Приложение А3),Инструкция по унифицированным методам микробиологических исследований при выявлении, диагностики и лечении туберкулеза
  84. Федеральные клинические рекомендации по организации и проведению микробиологической и молекулярно-генетической диагностики туберкулеза РОФ. – Москва. – 2015. ООО «Издательство «Триада», 2015. Тверь: – 46 с
  85. Patterson TF Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Aug 15; 63 (4): e1-e60. doi: 10.1093/cid/ciw326. Epub2016 Jun 29
  86. A.J. Ullmann et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline; Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12.
  87. Chabann MR, Kejner A, Rowe SM, Woodworth BA. Cystic fibrosis chronic rhinosinusitis: a comprehensive review. Am J Rhinol Allerg. 2013; 27: 387-95
  88. Roby BB, McNamara J, Finkelstein M, Sidman J. Sinus surgery in cystic fibrosis patients: Comparison of sinus and lower airway cultures. Int J Pediatr Otorhinolaryngol. 2008; 73: 1365-9
  89. Care of Children with Cystic Fibrosis Royal Brompton Hospital, 2020. The 8 th edition https://www.rbht.nhs.uk/sites/nhs/files/Cystic%20fibrosis%20guidelines/CF%20G%202020/CF%20guideline%202020%20FINAL_edited.pdf (8.7 Pseudo-Bartter’s syndrome https://www.rbht.nhs.uk/sites/nhs/files/Cystic%20fibrosis%20guidelines/CF%20G%202020/8.pdf)
  90. Stuart B. Mushlin, MD, Harry L. Greene, II MD Decision Making in Medicine: An Algorithmic Approach, 3 edition Elsevier Health Sciences, 2009;768p. https://books.google.ru/books?id=kdBRlPlU3aUC&printsec=frontcover&hl=ru&source=gbs_ge_summary_r&cad=0#v=onepage&q&f=false
  91. Middleton PG, Wagenaar M, Matson AG, Craig ME, HolmesWalker DJ, Katz T, et al. Australian standards of care for cystic fibrosis-related diabetes. Respirology 2014;19:185–92. https://doi. org/10.1111/resp.12227
  92. Moran A, Pillay K, Becker DJ, Acerini CL, International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2014;15(Suppl. 20):65–76. https://doi.org/10.1111/pedi.12178
  93. Prentice B, Hameed S, Verge CF, Ooi CY, Jaffe A, Widger J. Diagnosing cystic fibrosis-related diabetes: current methods and challenges. Expert Rev Respir Med 2016;10:799–811. https://doi.org /10.1080/17476348.2016.119064679, 80
  94. Boudreau V, Reynaud Q, Rabasa-Lhoret R. What is the Real Usefulness of Glycated Hemoglobin Levels for Diabetes Screening in Patients With Cystic Fibrosis? Can J Diabetes. 2019 Feb;43(1):1-2
  95. Yi Y, Norris AW, Wang K, Sun X, Uc A, Moran A, Engelhardt JF, Ode KL. Abnormal Glucose Tolerance in Infants and Young Children with Cystic Fibrosis. Am J Respir Crit Care Med. 2016 Oct 15;194(8):974-980
  96. Tangpricha V., Kelly A., Stephenson A. Et al.An Update on the Screening, Diagnosis, Management, and Treatment of Vitamin D Deficiency in Individuals with Cystic Fibrosis: Evidence-Based Recommendations from the Cystic Fibrosis Foundation   J Clin Endocrinol Metab, April 2012, 97(4):0000–0000 jcem.endojournals.org
  97. Lee J., Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markersin management of osteoporosis.Ann Lab Med 2012;32:105-112
  98. Репина С.А., Красовский С.А., Роживанов Р.В, Сорокина Т.М., Шилейко Л.В., Штаут М.И., Курило Л.Ф., Шмарина Г.В., Адян Т.А., Каширская Н.Ю., Поляков А.В., Черных В.Б. Андрологическое обследование пациентов с легочной и смешанной формой муковисцидоза. Андрология и генитальная хирургия. 2018. Т.19. №2. С.41-49. doi: 10.17650/2070-9781-2018-19-2-31-39
  99. Репина С.А., Красовский С.А., Сорокина Т.М., Курило Л.Ф., Штаут М.И., Адян Т.А., Поляков А.В., Черных В.Б. Патогенный вариант 3849+10kbC>T гена CFTR как главный предиктор сохранения фертильности у мужчин с муковисцидозом // Генетика. 2019 б. Т.55. №12. C1481–6. doi: 10.1134/S0016675819120105. (SCOPUS, WoS)
  100. Штаут М.И., Шилейко Л.В., Репина С.А., Красовский С.А., Шмарина Г.В., Сорокина Т.М., Курило Л.Ф., Черных В.Б. Комплексное сперматологическое обследование пациентов с муковисцидозом. Андрология и генитальная хирургия. 2017. T.18. №4. С.69–76. doi: 10.17650/2070-9781-2017-18-4-69-76
  101. Jungwirth A., Diemer T., Kopa Z., Krausz C., Minhas S., Tournaye H. EAU Guidelines on Male Infertility. European Association of Urology 2018. Male infertility - Limited update 2018. 46 pp. https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Male-Infertility-2018-large-text.pdf
  102. Leifke E., Friemert M., Heilmann M., Puvogel N., Smaczny C., vonzur Muhlen A., Brabant G. Sex steroid sand body composition in men with cystic fibrosis. Eur J Endocrinol 2003; 148:551–557.  doi: 10.1530/eje.0.1480551
  103. Blackman S. M., Tangpricha V. Endocrine Disordersin Cystic Fibrosis. Pediatric Clinics of North America 2016; 63(4): 699–708. doi:10.1016/j.pcl.2016.04.009
  104. Yoon J.C., CasellaJ.L., Litvin M., Dobs A.S. Male reproductive health in cystic fibrosis. J Cyst Fibros. 2019 Oct; 18 Suppl 2: S105-S110. doi: 10.1016/j.jcf.2019.08.007
  105. Baatallah N, Bitam S, Martin N, Servel N, Costes B, Mekki C, Chevalier B, Pranke I, Simonin J, Girodon E, Hoffmann B, Mornon JP, Callebaut I, Sermet-Gaudelus I, Fanen P, Edelman A, Hinzpeter A. Cis variants identified in F508del complex alleles modulate CFTR channel rescue by small molecules. Hum Mutat. 2018 Apr;39(4):506-514. doi: 10.1002/humu.23389. Epub 2018 Jan 16. PMID: 29271547
  106. Landsverk ML, Douglas GV, Tang S, Zhang VW, Wang GL, Wang J, Wong LJ. Diagnostic approaches to apparent homozygosity. Genet Med. 2012 Oct;14(10):877-82. doi: 10.1038/gim.2012.58. Epub 2012 May 17. PMID: 22595940
  107. Hantash FM, Rebuyon A, Peng M, Redman JB, Sun W, Strom CM . Apparent homozygosity of a novel frame shift mutation in the CFTR gene because of a large deletion. J Mol Diagn 2009;11:253–256
  108. RRechitsky S, Strom C, Verlinsky O, Amet T, Ivakhnenko V, Kukharenko V, Kuliev A, Verlinsky Y. Allele dropout in polar bodies and blastomeres. J Assist Reprod Genet. 1998 May;15(5):253-7. doi: 10.1023/a:1022532108472. PMID: 9604756; PMCID: PMC3454764
  109. Hantash FM, Redman JB, Goos D, Kammesheidt A, McGinniss MJ, Sun W, Strom CM. Characterization of a recurrent novel large duplication in the cystic fibrosis transmembrane conductance regulator gene. J Mol Diagn. 2007 Sep;9(4):556-60. doi: 10.2353/jmoldx.2007.060141. Epub 2007 Aug 9. PMID: 17690208; PMCID: PMC1975096
  110. Hantash FM, Redman JB, Starn K, Anderson B, Buller A, McGinniss MJ, Quan F, Peng M, Sun W, Strom CM. Novel and recurrent rearrangements in the CFTR gene: clinical and laboratory implications for cystic fibrosis screening. Hum Genet. 2006 Mar;119(1-2):126-36. doi: 10.1007/s00439-005-0082-0. Epub 2005 Dec 17. Erratum in: Hum Genet. 2006 Apr;119(3):352. PMID: 16362824
  111. Dekkers J.F., van der Ent C.K., Beekman J.M. Novel opportunities for CFTR-targeting drug development using organoids. Rare Dis. 2013;1(e27112) DOI: 10.4161/rdis.27112
  112. Boj S.F., Vonk A.M., Statia M. Su J., Vries R.R.G., Beekman J.M., Clevers H. Forskolin-induced swelling in intestinal organoids: an in vitro assay for assessing drug response in cystic fibrosis patients. J Vis Exp. 2017;120 :55159. DOI: 10.3791/55159
  113. Dekkers J.F. Berkers G., Kruisselbrink E., Vonk A., de Jonge H.R., Janssens H.M., Bronsveld I., van de Graaf E.A., Nieuwenhuis E.E.S., Houwen R.H.J., Vleggaar F.P., Escher J.C., de Rijke Y.B., Majoor C.J., Heijerman H.G.M., de Winter–de Groot K.M., Clevers H.,van der Ent C.K., Beekman J.M. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med. 2016; 8(344):344ra384. DOI: 10.1126/SCITRANSLMED.AAD8278
  114. Vonk A.M., van Mourik P., Ramalho A.S., Silva I.A.L.,  Statia M., Kruisselbrink E., Suen S.W.F., Dekkers J.F., Vleggaar F.P., Houwen R.H.J., Mullenders J., Boj S.F., Vries R., Amaral M.D., de Boeck K., van der Ent C.K., Beekman J.M. Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids. STAR Protoc. 2020 Jun 19; 1(1): 100019. DOI: 10.1016/J.XPRO.2020.10001
  115. Connett GJ. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Drug Des Devel Ther. 2019 Jul 19;13:2405-2412
  116. Berkers G, van Mourik P, Vonk AM, Kruisselbrink E, Dekkers JF, de Winter-de Groot KM, Arets HGM, Marck-van der Wilt REP, Dijkema JS, Vanderschuren MM, Houwen RHJ, Heijerman HGM, van de Graaf EA, Elias SG, Majoor CJ, Koppelman GH, Roukema J, Bakker M, Janssens HM, van der Meer R, Vries RGJ, Clevers HC, de Jonge HR, Beekman JM, van der Ent CK. Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis. Cell Rep. 2019 Feb 12;26(7):1701-1708.e3
  117. Southern KW, Patel S, Sinha IP, Nevitt SJ. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Cochrane Database Syst Rev. 2018 Aug 2;8(8):CD010966
  118. Кондратьева Е.И., Мельяновская Ю.Л., Ефремова А.С., Булатенко Н.В., Бухарова Т.Б., Гольдштейн Д.В., Зодьбинова А.Э., Никонова В.С., Жекайте Е.К., Каширская Н.Ю., Мелконян Г.Г., Одинаева Н.Д., Куцев С.И. Опыт применения методов оценки функциональности анионного канала CFTR у пациентов с установленным и предполагаемым диагнозом муковисцидоза. Сибирское медицинское обозрение. 2019; N 2.:С.60-69
  119. Magdalena Kołodziej, Michael J. de Veer, Marian Cholewa, Gary F. Egan, and Bruce R. Thompson Lung function imaging methods in Cystic Fibrosis pulmonary disease. Respir Res. 2017; 18: 96 Published online 2017 May 17. doi: 10.1186/s12931-017-0578-x
  120. Leutz-Shmidt P, Eichinger M, Stahl M, Sommerburg O, Biederer J, Kauczor HU, Puderbach MU, Mall MA, Wielputz MO, Ten years of chest MRI for patients with cystic fibrosis: Translation from the bench to clinical routine. Radiologe. 2019 Dec.59 (Suppl 1): 10-20
  121. Carter J M, Johnson BT, Patel A, Palacios E, Rodriguez KH. Lund-Mackay staging system in cystic fibrosis: a prognostic factor for revision surgery? The Ochsner Journal. 2014; 14: 184-7
  122. Kang SH, Dalcin PTR, Piltcher OB, Migliavacca RO. Chronic rhinosinusitis and nasal polyposis in cystic fibrosis: update on diagnosis and treatment. JBrasPneumol 2015; 41(1): 65-76
  123. Детская хирургия.Национальное руководство.под ред. Исакова Ю.Ф., Дронова А.Ф.- ГЭОТАР - Медиа.- 2009.- стр. 328-331
  124. De Backer AI, De Schepper AM, Deprettere A, Van Reempts P, Vaneerdeweg W. Radiographic manifestations of intestinal obstruction in the newborn. JBR-BTR. 1999 Aug;82(4):159-66
  125. Sermet-GaudelusI, BianchiML, GarabedianM, ArisRM, MortonA, HardinDS, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 2011;10(2):S16–23
  126. Cystic Fibrosis Trust UK. Bone mineralisation in cystic fibrosis. CysticFibrosisTrust: Bromley; 2007.
  127. Скрипникова И.А., Щеплягина ЛА., Новиков В.Е., Косматова О.В., Абирова А.С. Возможности костной рентгеновской денситометрии в клинической практике. Методические рекомендации, 2-е издание, дополненное. Москва, 2015 г
  128. Hardinge M, Annandale J, Bourne S, Cooper B, Evans A, Freeman D, Green A, Hippolyte S, Knowles V, MacNee W1, McDonnell L, Pye K, Suntharalingam J, Vora V, Wilkinson T; British Thoracic Society Home Oxygen Guideline Development Group; British Thoracic Society Standards of Care Committee British Thoracic Society guidelines for home oxygen use in adults Thorax. 2015 Jun;70 Suppl 1:i1-43. doi: 10.1136/thoraxjnl-2015-206865
  129. Don Hayes, Jr., Kevin C. Wilson, Katelyn Krivchenia, Stephen M. M. Hawkins, Ian M. Balfour-Lynn, David Gozal, Howard B. Panitch, Mark L. Splaingard, Lawrence M. Rhein, Geoffrey Kurland, Steven H. Abman, Timothy M. Hoffman, Christopher L. Carroll, Mary E. Cataletto, Dmitry Tumin, Eyal Oren, Richard J. Martin, Joyce Baker, Gregory R. Porta, Deborah Kaley, Ann Gettys, and , on behalf of the American Thoracic Society Assembly on Pediatrics Home Oxygen Therapy for Children. An Official American Thoracic Society Clinical Practice Guideline Am J Respir Crit Care Med. 2019 Feb 1; 199(3): e5–e23
  130. Lam S, Nettel-Aguirre A, Van Biervliet S, Roeb E, Sadler MD, Friedrich-Rust M, Karlas T, Kitson MT, deBruyn JCC. Transient Elastography in the Evaluation of Cystic Fibrosis-Associated Liver Disease: Systematic Review and Meta-analysis. J Can Assoc Gastroenterol. 2019 May;2(2):71-80
  131. Jungwirth A., Giwercman A, Tournaye H, Diemer T, Kopa Z, Dohle G, Krausz C; European Association of Urology Working Group on Male Infertility. European Association of Urology guidelines on Male Infertility: the 2012 update. Eur Urol. 2012 Aug;62(2):324-32. doi: 10.1016/j.eururo.2012.04.048
  132. Snežana Živanović, Ljiljana Šaranac, Gordana Kostić The case of pseudo-Bartter"s syndrome: an atypical presentation of cystic fibrosis Facta universitatis Series: Medicine and Biology Vol.15, No 1, 2008, pp. 33 - 36 UC 616-056.7-053.2
  133. Franco LP, Moreira Camargos PA, Maria Gonçalves Becker HM, Eustáquio Santos RE.  Nasal endoscopic evaluation of children and adolescents with cystic fibrosis Guimarães Braz J Otorhinolaryngol.2009; 75(6):806-13
  134. Поляков Д.П., Карнеева О.В., Белавина П.И. Хронический риносинусит у детей с муковисцидозом: современные тенденциии собственный опыт 2018;26(4):17-25
  135. Okafor S, Kelly KM, Halderman AA. Management of Sinusitis in the Cystic Fibrosis Patient. Immunol Allergy Clin North Am. 2020 May;40(2):371-383
  136. Mohamad R. Chaaban, M.D., Alexandra Kejner, M.D., Steven M. Rowe, M.D., and Bradford A. Woodworth, M.D. Cystic fibrosis chronic rhinosinusitis: A comprehensive review.Am J Rhinol Allergy. 2013 Sep-Oct; 27(5): 387–39538-42
  137. Hug MJ, Derichs N, Bronsveld I, Clancy JP. Measurement of ion transport function in rectal biopsies. Methods Mol Biol. 2011;741:87-107. DOI: 10.1007/978-1-61779-117-8_7
  138. Domenique D, Zommer-van Ommen, Eyleen de Poel, Evelin Krusselbrink, Hugo Oppelar, Annelote M Vonk, Hettie M Janssens, Cornelis K vander Ent, Marne C Hagemeijer, Jeffrey M Beekman  Comparison of Ex Vivo and in Vitro Intestinal Cystic Fibrosis Models to measure CFTR-dependent Ion Chanel Activity. 2018 May;17(3):316-324
  139. Carlyle B.E., Borowitz D.S., Glick P.L. A review of pathophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. J. Pediat. Surg. 2012; 47: 72—81
  140. Munck A, Alberti C, Colombo C, Kashirskaya N, Ellemunter H, Fotoulaki M, Houwen R, Robberecht E, Boizeau P, Wilschanski M; CF/Pancreas ESPGHAN Working Group and DIOS Study Group. International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcome. J Cyst Fibros. 2016 Jul;15(4):531-9. doi: 10.1016/j.jcf.2016.02.002
  141. Sandy NS, Massabki LHP, Gonçalves AC, Ribeiro AF, Ribeiro JD, Servidoni MFCP, Lomazi EA. Distal intestinal obstruction syndrome: a diagnostic and therapeutic challenge in cystic fibrosis. J Pediatr (Rio J). 2020 Nov-Dec;96(6):732-740
  142. Canny JD, Brookes A, Bowley DB. Distal intestinal obstruction syndrome and colonic pathologies in cystic fibrosis. Br J Hosp Med (Lond). 2017 Jan 2;78(1):38-43
  143. Alattar Z, Thornley C, Behbahaninia M, Sisley A. Proximal small bowel obstruction in a patient with cystic fibrosis: a case report. Surg Case Rep. 2019 Sep 13;5(1):143
  144. Abicht T, Jones C, Coyan G, Stites S, Moncure M. A technique for the surgical treatment of distal intestinal obstructive syndrome by hand-assisted laparoscopy. Surg Laparosc Endosc Percutan Tech. 2012 Jun;22(3):e142-3
  145. Luciana M.N. Martins a, Paulo A.M. Camargos, Helena M.G. Becker, Celso G. Becker, Roberto E.S. Guimaraes. Hearing loss in cystic fibrosis//International Journal of Pediatric Otorhinolaryngology 2010 – 74: 469–473; 3.
  146. Care of children with cystic fibrosis. ENT complications. Royal Brompton and Harefield, 2017. http://www.rbht.nhs.uk/healthprofessionals/clinical-departments/cystic-fibrosis/clinical-cf-guidelines-care-of-children/other-non-pulmonary-complications-of-cf/ent-complications/;
  147. Kathryn L Kreicher , Michael J Bauschard , Clarice S Clemmens, Concetta Maria Riva,  Ted A Meyer 5 Audiometric Assessment of Pediatric Patients With Cystic Fibrosis J Cyst Fibros2018 May;17(3):383-390
  148. Хирургические болезни недоношенных детей. Национальное руководство: под ред. Козлова Ю. АК., Новожилова В.А., Разумовский А.Ю.: ГЭОТАР- Медиа.- 2019.- стр. 329-393
  149. Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2018 Sep 6;9:CD001127
  150. Casale M, Vella P, Moffa A, Oliveto G, Sabatino L, Grimaldi V, Ferrara P, Salvinelli F. Hyaluronic acid and upper airway inflammation in pediatric population: a systematic review. Int J Pediatr Otorhinolaryngol. 2016 Jun;85:22-6.
  151. Wark P, McDonald VM Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2018 Sep 27;9:CD001506. doi: 10.1002/14651858.CD001506.pub4
  152. Nevitt Sj, Thornton J, Murray Cs, Dwyer T. Inhaled mannitol for cystic fibrosis. Cochrane Database Syst Rev. 2018 Feb 9;2:CD008649
  153. Шерман В.Д., Воронкова А.Ю., Кондратьева Е.И., Жекайте Е.К., Черняк А.В. Опыт применения препарата маннитол** (Бронхитол-Фармаксис) у пациентов детского возраста с муковисцидозом в Московском регионе. Пульмонология, том 29, №4, 2019, стр.436-442
  154. Ziebach R, Pietsch-Breitfeld B, Bichler M, Busch A, Riethmüller J, Stern M. Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatr Pulmonol. 2001 Jun;31(6):431-5
  155. Avital A, Sanchez I, Chernick V.Efficacy of salbutamol and ipratropium bromide in decreasing bronchial hyperreactivity in children with cystic fibrosis. Pediatr Pulmonol. 1992 May;13(1):34-7
  156. Smith S, Edwards CT. Long-acting inhaled bronchodilators for cystic fibrosis.Cochrane Database Syst Rev. 2017 Dec 19;12:CD012102
  157. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis.Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003428
  158. F. Ratjen, A. Munck, P. Kho, G. Angyalosi Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010 ;65 (4) : 286-291.
  159. G. Taccetti, E. Bianchini, L. Cariani. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: A randomised multicentre study comparing two different protocols. Thorax. 2012; 67 (10) :853-859.
  160. M. Proesmans, F. Vermeulen, L. Boulanger, J. Verhaegen, K. De Boeck. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros. 2013; 12(1):29-34.
  161. P.A. Flume, P.J. Mogayzel, K.A. Robinson Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations. Am. J. Respir. Crit. Care Med. 2009; 180: 802–808.
  162. McKinzie CJ, Chen L, Ehlert K, Grisso AG, Linafelter A, Lubsch L, O"Brien CE, Pan AC, Wright BA0, Elson EC.Off-label use of intravenous antimicrobials for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2019 Nov;54 Suppl 3:S27-S45
  163. Antibiotic treatment for cystic fibrosis. in: Report of the UK Cystic Fibrosis Trust Antibiotic Group. UK Cystic Fibrosis Trust, London; 2009, Consensus document on antibiotic treatment for cystic fibrosis. Published: May 2009
  164. Solis, A., Brown, D., Hughes, J. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol. Ped Pulmonology. 2003; 36: 189–95
  165. Zobell JT, Epps KL, Young DC, Montague M, Olson J, Ampofo K, Chin MJ, Marshall BC Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol. 2015 Jun;50(6):552-9. doi: 10.1002/ppul.23132. Epub 2015 Jan 5
  166. Mark T Jennings, Michael P Boyle, David Weaver, Karen A Callahan, and Elliott C Dasenbrook Eradication strategy for persistent methicillin-resistant infection in individuals with cystic fibrosis—the PMEP trial: study protocol for a randomized controlled trial.Trials. 2014; 15: 223. doi: 10.1186/1745-6215-15-223
  167. Kiefer A, Bogdan C, Melichar VO. Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme. BMC Pulm Med. 2018 Jan 25;18(1):20. doi: 10.1186/s12890-018-0588-6
  168. Maiz, L., Canton, R., Mir, N. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Ped Pulmonology. 1998; 26: 287–9
  169. Weathers, L., Riggs, D., Santeiro, M. Aerosolized vancomycin for treatment of airway colonization by methicillin resistant Staphylococcus aureus [letter]. Ped Infect Dis J. 1990; 9
  170. Jennings MJ, Boyle MP, Bucur C, Konstan MW, Dasenbrook EC. Pharmacokinetics and safety of inhaled vancomycin in patients with cystic fibrosis. Pediatr Pulmonol. 2012;47:320
  171. Mann HJ, Canafax DM, Cipolle RJ, et al. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr. Pulmonol. 1985; 1: 238–43
  172. De Groot R, Hack BD, Weber A, et al. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study. Clin. Pharmacol. Ther. 1990; 47: 73–8
  173. De Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin. Pharmacokinet. 1987; 13: 228–53
  174. Horrevorts AM, de Witte J, Degener JE, et al. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment. Chest. 1987; 92: 844–8
  175. Stutman HR, Shalit I, Marks MI, et al. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. Am. J. Med. 1987; 82: 142–5
  176. Государственный Реестр лекарственных средств: https://grls.rosminzdrav.ru
  177. Mitchell JP. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2012 Apr;39(4):1054-5
  178. Physiotherapy for People with Cystic Fibrosis: from Infant to Adult. 7th edition 2019 https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/IPG%20CF_Blue%20Booklet_7th%20edition%202019.pdf.
  179. L. Loader, O. Sewell, S. Gammie Survey of home infusion care in England. Am. J. Health Syst. Pharm; 2000:57(8):763-766
  180. Poole S. M. Intravenous push medications in the home / S. M. Poole, A. Nowobilsfti-Vasilios, F. Free // J. Intraven. Nurs. – 1999. – Vol. 22, № 4. – P. 209-215
  181. Осипова И.А., Блистинова 3.A., Капранов A.H., Пятова С.В. Опыт внутривенной антибактериальной терапии на дому у детей, больных муковисцидозом. «Пульмонология» 2001г., № 3, стр. 27-31
  182. Блистинова З.А. Клиническое значение стационарозамещающих технологий при лечении реабилитации и медико-социальной адаптации больных муковисцидозом. Автореферат дисс. …канд.мед.наук 2002 – 26с.
  183. Boyle MP.Persistent methicillin resistant Staphylococcus aureus eradication protocol (PMEP). Clinicaltrials.Gov. NLM identifier: NCT01594827. Bethesda, MD: National Library of Medicine (US). 2012[accessed 2014 Jan 20]. Available from: http://clinicaltrials.Gov/ct2/show/nct01594827
  184. James F. Chmiel, Timothy R. Aksamit, Sanjay H. Chotirmall, Elliott C. Dasenbrook, J. Stuart Elborn, John J. LiPuma, Sarath C. Ranganathan, Valerie J. Waters, and Felix A. Ratjen Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections Ann Am Thorac Soc. 2014 Sep; 11(7): 1120–1129,
  185. Döring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012 Dec;11(6):461-79
  186. Garazzino S, Altieri E, Silvestro E, Pruccoli G, Scolfaro C, Bignamini E. Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data. Front Pediatr. 2020 May 5;8:173
  187. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Ceftolozane-tazobactam_Rationale_1.0_20200515_v1.pdf
  188. R. Morton, S.Doe, W.Banya, N.J. Simmond. Clinical benefit of continuous nebulised Aztreonam Lysine for Inhalation (AZLI) in adults with cystic fibrosis – a retrospective cohort study/ Jornal Cystic Fibrosis Vol 16 Suppl 1 (2017) S 55.
  189. Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros. 2005 Aug;4 Suppl 2:49-54
  190. Smith S, Rowbotham NJ, Regan KH. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev. 2018 Mar 30;3:CD001021
  191. Ratjen F, Moeller A et al. Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study. 2018 http://www.cysticfibrosisjournal.com/article/ S1569-1993(18)30087
  192. Regan KH, Bhatt J.Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev. 2019 Apr 18;4:CD009876
  193. Frost F, Shaw M, Nazareth D. Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev. 2019 Jun 13;6:CD013079
  194. Weidmann A, Webb AK, Dodd ME, Jones AM. Successful treatment of cepacia syndrome with combination nebulised and intravenous antibiotic therapy. J Cyst Fibros. 2008 Sep;7(5):409-11
  195. Aaron SD, Ferris W, Henry DA, Speert DP, MacDonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000;161:1206–12
  196. Etherington C, Peckham DG, Conway SP, et al. Burkholderia cepacia complex infection in adults with cystic fibrosis – is early eradication possible? J. Cyst. Fibrosis. 2003; 2: 220–1
  197. Grimwood K, Kidd TJ, Tweed M. Successful treatment of cepacia syndrome. J Cyst Fibros. 2009;8 (4): 291-293. doi: 10.1016/j.jcf.2009.04.002
  198. Красовский С.А., Бутюгина И.Н., Амелина Е.Л., Усачева М.В., Грачева О.Ю. Совместное внутривенное применение двух бета-лактамных антибиотиков в составе комплексной антибактериальной терапии у взрослых больных муковисцидозом. ХХVII Национальный конгресс по болезням органов дыхания, 2017. Сборник трудов: 89.
  199. Abbott IJ, Peleg AY.Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies. Semin Respir Crit Care Med. 2015 Feb;36(1):99-110
  200. Colin E. Swenson and Ruxana T. Sadikot Achromobacter Respiratory Infections Annals  ATS Volume 12 Number 2| February 2015 Р252-258
  201. Dupont C, Jumas-Bilak E, Michon AL, Chiron R, Marchandin H. Impact of High Diversity of Achromobacter Populations within Cystic Fibrosis Sputum Samples on Antimicrobial Susceptibility Testing. J Clin Microbiol. 2016 Dec 28;55(1):206-215
  202. Wang M, Ridderberg W, Hansen CR, Høiby N, Jensen-Fangel S, Olesen HV, Skov M, Lemming LE, Pressler T, Johansen HK, Nørskov-Lauritsen N. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. J Cyst Fibros. 2013 Dec;12(6):638-43
  203. B. D. Edwards, J. Greysson-Wong, R. Somayaji, B. Waddell, F. J. Whelan, D. G. Storey, H. R. Rabin, M. G. Surette, and M. D. Parkins, Betty A. Forbes Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study J Clin Microbiol. 2017 Jul; 55(7): 2074–2085
  204. CLSI. Susceptibility testing of Mycobacteria, Nocardiae, and Aerobic Actinomycetes: Approved Standards, Second Edition. M24-2, Vol. 26, No.23, 2007. Clinical and Laboratory Standards Institute, USA
  205. Charles S Haworth, John Banks, Toby Capstick, Andrew J Fisher, Thomas Gorsuch, Ian F Laurenson, Andrew Leitch, Michael R Loebinger, Heather  Milburn, Mark Nightingale, Peter Ormerod, Delane Shingadia, David Smith, Nuala Whitehead, Robert Wilson, R Andres Floto British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) Thorax Nov 2017, 72 (Suppl 2) ii1-ii64; DOI: 10.1136/thoraxjnl-2017-210927
  206. R.A. Floto, K.N. Olivier, L. Saiman, C.L. Daley, J-L. Herrmann, J.A. Nick, P. G. Noone, D.Bilton, P.Corris, R.L. Gibson, S.E. Hempstead, K.Koetz, K.A. Sabadosa, I..Sermet-Gaudelus, A.R.Smyth, J. van Ingen, R. J. Wallace, K. L. Winthrop, B. C..Marshall, C.S. Haworth. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis December 2015 Thorax 71(Suppl 1):i1-i22 DOI: 10.1136/thoraxjnl-2015-207360
  207. Согласованные рекомендации Американского фонда кистозного фиброза (муковисцидоза) и Европейского общества кистозного фиброза по лечению микобактериоза у пациентов с кистозным фиброзом. С-Пб.: Благотворительный фонд «Острова», 2017 г. – 32с. Редактор перевода Н.Ю.Каширская. ISBN 978-5-9906416-6-2
  208. Федеральные клинические рекомендации по организации и проведению микробиологической и молекулярно-генетической диагностики туберкулеза РОФ. – Москва. – 2015. ООО «Издательство «Триада», 2015. Тверь: – 46 с.
  209. Bange FC, Böttger EC. Improved decontamination method for recovering mycobacteria from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2002 и 21:546–8
  210. Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massillense infection and inducible resistance. Am J Respir Crit Care Med 2012:186:917–25
  211. Maurer FP, Castelberg C, Quiblier C, et al. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. J Antimicrob Chemother 2014:69:1559–63
  212. Maurer FP, Bruderer VL, Ritter C, et al. Lack of antimicrobial bactericidal activity in Mycobacterium abscessus. Antimicrob Agents Chemother 2014:58:3828–36
  213. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007 и 175:367–416
  214. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004:38:1538–44
  215. Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006 и 174:928–34
  216. Jenkins PA, Campbell IA, Banks J, et al. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008 и 63:627–34
  217. Griffith DE, Brown BA, Girard WM, et al. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;594–8., 21
  218. Griffith DE, Brown BA, Girard WM, et al. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996;23:983–9
  219. Griffith DE, Brown BA, Wallace RJ Jr. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus—negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. Clin Infect Dis 1996;23:1321–2
  220. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria.I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003:167:828–34
  221. Martiniano SL, Sontag MK, Daley CL, et al. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc 2014 ;11:36–44
  222. Schwiesow JN, Iseman MD, Peloquin CA. Concomitant use of voriconazole andrifabutin in a patient with multiple infections. Pharmacotherapy 2008;28:1076–80
  223. Krishna G, Parsons A, Kantesaria B, et al. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007;23:545–52
  224. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003;124:1482–6
  225. Козлова Я.И., Борзова Ю.В., Суслова И.Е., Богомолова Т.С., Аак О.В., С.М. Игнатьева, Степаненко Т.С.,Орлов А.В., Красовский С.А., Климко Н.Н. Аспергиллез легких у больных муковисцидозом. Журнал инфектологии – 2018, Т 10, № 2
  226. Proesmans M, Vermeulen F, Vreys M, De Boeck K. Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Int J Pediatr. 2010;2010:376287. doi: 10.1155/2010/376287
  227. Hayes D, Jr, Murphy BS, Lynch JE, Feola DJ. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatr Pulmonol. 2010;45:1145–8
  228. Elphick HE, Southern KW Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2016 Nov 8; 11: CD002204
  229. Lattanzi C, Messina G, Fainardi V, Tripodi MC, Pisi G, Esposito S. Allergic Bronchopulmonary Aspergillosis in Children with Cystic Fibrosis: An Update on the Newest Diagnostic Tools and Therapeutic Approaches. Pathogens. 2020 Aug 31;9(9):716
  230. Ibrahim Ahmed Janahi, Abdul Rehman, and Amal Rashid Al-Naimi Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.Ann Thorac Med. 2017 Apr-Jun; 12(2): 74–82, Jitendra Sisodia; Tushar BajajAllergic Bronchopulmonary Aspergillosis Treasure Island (FL): StatPearls Publishing; 2021 Jan https://www.ncbi.nlm.nih.gov/books/NBK542329/
  231. https://mukoviscidoz.org/doc/med_doc/otvet-farmakologov.pdf
  232. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/fibrosing-colonopathy: Thomas F.Burks, Глава10.08.3.2.3 Pancreatic enzyme preparations
  233. Somaraju, U.R. and Solis-Moya, A. Pancreatic enzyme replacement therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 2014; 10: CD008227
  234. Meyer JH, Elashoff J, Porter-Fink V, Dressman J, Amidon GL. Human postprandial gastric emptying of 1-3 millimeter spheres. Gastroenterology 1988; 94: 1315-25
  235. Mundlos S, Kuehnelt P, Adler G. Monitoring enzyme re-placement treatment in exocrine pancreatic insufficiency using the cholesteryl octanoate breath test. Gut 1990;31:1324-1328
  236. Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in Cystic Fibrosis. J Cyst Fibros. 2017 Nov;16 Suppl 2:S70-S78
  237. J. Calvo-Lerma, J. Hulst, I. Asseiceira, I. Claes, M. Garriga, C. Colombo [et al.]Nutritional status, nutrients intake and enzymatic supplements in a European Cystic Fibrosis cohort: a cross-sectional overview / Journal of Cystic Fibrosis.2016:15(1):S3
  238. Calvo-Lerma J,Martinez-Jimenez CP, LázaroRamos J-P, et al. Innovative approach for self-management and social welfare of children with cystic fibrosis in Europe: development, validation and implementation of an mHealth tool (MyCyFAPP).BMJ Open 2017;7:e014931.doi:10.1136/bmjopen-2016-014931
  239. J. Calvo-Lerma, J. Hulst, I. Asseiceira, I. Claes, M. Garriga, C. Colombo [et al.] Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines. J Cyst Fibros. 2017 Jul;16(4):510-518. doi: 10.1016/j.jcf.2017.03.005
  240. J. Calvo-Lerma, V. Fornés-Ferrer, A. Heredia, A. Andrés J. In Vitro Digestion of Lipids in Real Foods: Influence of Lipid Organization Within the Food Matrix and Interactions with Nonlipid Components / J Food Sci. 2018 Oct;83(10):2629-2637
  241. Кондратьева Е. И., Орлов А. В., Максимычева Т. Ю., Никитина М. И., Пашкевич А. А. Возможности оптимизации ферментной терапии при муковисцидозе // Педиатрия. 2018. №    97 (6). С. 116–124
  242. Кондратьева Е. И., Максимычева Т. Ю., Ильенкова Н. А., Чикунов В. В., Назаренко Л. П. Анализ разных подходов к назначению ферментов при хронической панкреатической недостаточности // Гастроэнтерология Санкт-Петербурга. Материалы 19-го Международного медицинского Славяно-Балтийского научного форума «Санкт-Петербург – Гастро–2017». 2017. № 1. С. 84
  243. Кондратьева Е. И., Максимычева Т. Ю., Ильенкова Н. А., Чикунов В. В., Назаренко Л. П., Смирнова И. И. Опыт применения компьютерной программы для оценки питания при муковисцидозе в РФ // Тезисы. 24-й конгресс детских гастроэнтерологов России и стран СНГ. 2017. С. 84
  244. Максимычева Т. Ю., Ильенкова Н. А., Чикунов В. В., Назаренко Л. П., Смирнова И. И. Опыт применения компьютерной программы для оценки питания при муковисцидозе в РФ / Тезисы. ХIII Национальный конгресс с международным участием «Инновационные достижения в диагностике и терапии муковисцидоза» (27–28 апреля 2017 г., г. Сергиев Посад, Московская область). С. 40–42
  245. Кондратьева Е. И., Максимычева Т. Ю., Ильенкова Н. А., Чикунов В. В., Назаренко Л. П., Смирнова И. И. Первый опыт расчета дозы панкреатина на фактическое содержание жира в пище с использованием программы «Мониторинг нутритивного статуса, рациона питания и ферментной терапии». // Тезисы. ХIII Национальный конгресс с международным участием «Инновационные достижения в диагностике и терапии муковисцидоза» (27–28 апреля 2017 г., г. Сергиев Посад, Московская область). С. 42–44
  246. Brodsky J, Dougherty S, Ramkrishna M, Rubenstein RC, Kelly A. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care. 2011;34:292-295. doi: 10.2337/dc10-1604
  247. Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treat cystic fibrosis related diabetes. J Cyst Fibros 2009;8(3):174-8. doi: 10.1016/j.jcf.2008.12.001
  248. van der Feen, C., van der Doef, H.P., van der Ent, C.K., and Houwen, R.H. Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. J Cyst Fibros. 2016; 15: 834–838 https://doi.org/10.1016/j.jcf.2016.07.009
  249. Cheng K, Ashby D, Smyth RL, Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 2011;10(2):S29–36. http://dx.doi.org/10.1016/ S1569-1993(11)60006-4
  250. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev. 2017 Sep 11;9:CD000222
  251. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Федосьина Е.А., Бессонова Е.Н., Пирогова И.Ю., Гарбузенко Д.В. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):71-102. https://doi.org/10.22416/1382-4376-2016-26-4-71-102
  252. Marquette M., Haworth C.S. Bone health and disease in cystic fibrosis. Paediatr Respir Rev 2016;20:2–5. https://doi.org/10.1016/j. prrv.2016.06.003
  253. E. Zhekaite, E. Kondratyeva, N. Ilenkova, V. Chikunov, L. Klimov, S. Dolbnya, A. Voronkova, V. Sherman, Y. Melyanovskaya, N. Dzhumaeva. The model for determining risk groups for the development of vitamin D deficiency and prevention algorithm in children with cystic fibrosis using the multifactor dimensionality reduction method. Journal of Cystic Fibrosis 20S1 (2021) S34.
  254. Жекайте Е.К. изучение влияния генетических и экзогенных факторов на развитие дефицита витамина  D у детей и подростков с муковисцидозом в возрастном аспекте. Вопросы профилактики: автореф. дис… канд. мед.наук. М., 2020
  255. А.А. Баранов, Л.С. Намазова-Баранова, О.И. Симонова, Н.Ю. Каширская, Е.А. Рославцева, Ю.В. Горинова, С.А. Красовский, Л.Р. Селимзянова Современные представления о диагностике и лечении детей с муковисцидозом //Педиатрическая фармакология. – 2015. – Т. 12. – №. 5
  256. Conwell LS, Chang AB.Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2014 Mar 14;(3):CD002010
  257. Ward LM., Konji1 VN, Ma J. The management of osteoporosis in children. Osteoporosis Int., 2016 Jul;27(7):2147-2179. doi: 10.1007/s00198-016-3515-9
  258. R. Harvey, S.A. Hannan,  L. Badia G Scadding Nasal saline irrigations for the symptoms of chronic rhinosinusitis. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006394
  259. W.J. Fokkens, V.J. Lund, J. Mullol et al. European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists Rhinol Suppl. 2012 Mar (23): 17298
  260. Beer H, Southern KW, Swift AC. Topical nasal steroids for treating nasal polyposis in people with cystic fibrosis. Cochrane Database Syst Rev. 2015 Jun 22;(6):CD008253. doi: 10.1002/14651858.CD008253.pub4
  261. King CS, Brown AW, Aryal S, Ahmad K, Donaldson S. Critical Care of the Adult Patient With Cystic Fibrosis. Chest. 2019 Jan;155(1):202-214. doi: 10.1016/j.chest.2018.07.025. Epub 2018 Aug 2
  262. Flume PA. Pneumothorax in cystic fibrosis. CurrOpinPulm Med.  2011 Jul;17(4):220-5. doi: 10.1097/MCP.0b013e328345e1f8
  263. Monroe EJ, Pierce DB, Ingraham CR, Johnson GE, Shivaram GM, Valji K. An Interventionalist"s Guide to Hemoptysis in Cystic Fibrosis. Radiographics. 2018 Mar-Apr;38(2):624-641. doi: 10.1148/rg.2018170122
  264. Flume, P.A., Mogayzel, P.J., Robinson, K.A., Rosenblatt, R.L., Quittell, L., Marshall, B.C. et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010; 182: 298–306
  265. Flume, P.A., Yankaskas, J.R., Ebeling, M., Hulsey, T., and Clark, L.L. Massive hemoptysis in cystic fibrosis. Chest. 2005; 128: 729–738 https://doi.org/10.1378/chest.128.2.729
  266. Mehta S, Hill NS. Noninvasive ventilation.  Am J Respir Crit Care Med.  2001 Feb;163(2):540-77
  267. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. Consensus conference. Chest.  1999 Aug;116(2):521-34.  DOI:  10.1378/chest.116.2.521
  268. Kapnadak SG, Dimango E, Hadjiliadis D, Hempstead SE, Tallarico E, Pilewski JM, Faro A, Albright J, Benden C, Blair S, Dellon EP, Gochenour D, Michelson P, Moshiree B, Neuringer I, Riedy C, Schindler T, Singer LG, Young D, Vignola L, Zukosky J, Simon RH. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. J Cyst Fibros. 2020 Feb 27. pii: S1569-1993(20)30064-3. doi:0.1016/j.jcf.2020.02.015. [Epub ahead of print]
  269. Carlyle B.E., Borowitz D.S., Glick P.L. A review of pathophysiology  and management of fetuses and neonates with meconium ileus for the  pediatric surgeon. J. Pediat. Surg. 2012; 47: 72—81
  270. Shinohara T., Tsuda M., Koyama N. Management of meconiumrelated ileus in very low-birthweight infants. Pediat. Int.2007; 49:  641—4
  271. Parikh NS, Ahlawat R. Meconium Ileus. [Updated 2020 Jan 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537008/
  272. Colombo C,  Ellemunter H,  Houwen R,  Munck A,  Taylor C,  Wilschanski M;  ECFS Guidelines for the diagnosis and management of  distal  intestinal obstruction  syndrome in cystic fibrosis patients. J Cyst Fibros.  2011 Jun;10 Suppl 2:S24-8. doi: 10.1016/S1569-1993(11)60005-2
  273. Abigail L. Schauble, PharmD,  Elizabeth K. Bisaccia, PharmD, Grace Lee, MD, and Samya Z. Nasr, MD N-acetylcysteine for Management of Distal Intestinal Obstruction Syndrome.J Pediatr Pharmacol Ther. 2019 Sep-Oct; 24(5): 390–397
  274. Green J, Carroll W, Gilchrist FJ. Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis. Cochrane Database Syst Rev. 2018 Aug 3;8:CD012798
  275. Wu HX, Zhu M, Xiong XF, Wei J, Zhuo KQ, Cheng DY. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.  Adv Ther. 2019 Feb;36(2):451-461. doi: 10.1007/s12325-018-0860-4
  276. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF,  Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547
  277. Balfour-Lynn IM,  Welch K,  Smith S. Inhaled  corticosteroids  for  cystic fibrosis.Cochrane Database Syst Rev.  2019 Jul 4;7:CD001915
  278. Mayer-Hamblett N,  Retsch-Bogart G,  Kloster M,  Accurso F,  Rosenfeld M,  Albers G,  Black P,  Brown P,  Cairns A,  Davis SD,  Graff GR,  Kerby GS,  Orenstein D,  Buckingham R,  Ramsey BW;  OPTIMIZE Study Group Azithromycin for Early Pseudomonas Infection in  Cystic Fibrosis. The OPTIMIZE Randomized Trial.  Am J Respir Crit Care Med.  2018 Nov 1;198(9):1177-1187
  279. Nichols DP, Odem-Davis K, Cogen JD, Goss CH, Ren CL, Skalland M, Somayaji R, Heltshe SL. Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. Am J Respir Crit Care Med. 2020 Feb 15;201(4):430-437
  280. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2012 Nov 14;11:CD002203
  281. Alexander L Pukhalsky, Galina V Shmarina, Nikolai I Kapranov, Svetlana N Kokarovtseva, Daria Pukhalskaya, and Natalia J Kashirskaja Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm. 2004 Apr; 13(2): 111–117
  282. Konstan MW, Schluchter MD, Storfer-Isser, Davis PB. Use of ibuprofen for the treatment of airway in flammation in CF: an update. Ped Pulmunol. 2002; Suppl 24: 164. Lands LC, Milner R, Cantin AM, Manson D, Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr. 2007; 151: 249-54.
  283. Schluchter MD, Konstan MW, Xue L, Davis PB. Relationship between high-dose ibuprofen use and rate of decline in FEV1 among young patients with mild lung disease in the CFF Registry. Ped. Pulmunol.  2004; Suppl. 27: 322.
  284. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2019 Sep 9;9:CD001505
  285. Rodriguez LA, Patrignani P. The ever growing story of cyclooxygenase inhibition. Lancet. 2006; 368: 1745-7.].
  286. Пухальский А.Л., Шабалова Л.А., Шмарина Г.В., Капранов Н.И., Кокаровцева С.Н. Использование нимесулида в лечении больных муковисцидозом. Пульмонология. 2001; 3: 46-50.].
  287. Roslavtseva E, Simonova O, Lokhmatov M, Gordeeva I Lactase activity in small intestinal biopsies in children with CF (continued) J Cystic Fibrosis 2018 Vol 17 Suppl 3 (June 2018) P. 108
  288. Руководство по клиническому питанию под редакцией В.М. Луфта, изд. 3-е переработанное, Арт-Экспресс СПб: 2016г.,409с
  289. WHO AnthroPlus for personal computers Manual: Software for assessing growth of the world"s children and adolescents. Geneva: WHO, 2009 (http://www.who.int/growthref/tools/en/)
  290. Программа оптимизации вскармливания детей первого года жизни в Российской Федерации: методические рекомендации / ФГАУ «НМИЦ здоровья детей» Минздрава России. М.: б. и., 2019. – C. 70-71
  291. M. Sinaasappel, M. Stern, J. Littlewood, S. Wolfe, G. Steinkamp, Harry G.M. Heijerman.  Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibrosis. 2002 (1): 51–75.
  292. Кондратьева Е.И., Жекайте Е.К., Одинаева Н.Д., Воронкова А.Ю., Шерман В.Д., Лошкова Е.В., Мельяновская Ю.Л., Зодьбинова А.Э., Шубина Ю.Ф., Будзинский Р.М. Динамика показателей обеспеченности витамином D страдающих муковисцидозом детей Московского региона за 2016–2018 гг. Вопросы питания, 20202, № 2, с 56-60
  293. Кондратьева Е. И., Максимычева Т. Ю., Портнов Н. М., Ильенкова Н. А., Пырьева Е. А., Чикунов В. В., Назаренко Л. П., Смирнова И. И. Первые результаты применения компьютерной программы «Мониторинг нутритивного статуса, рациона питания и ферментной терапии» // Вопросы детской диетологии. 2016. Т. 14, № 6. С. 5–12
  294. Максимычева Т. Ю., Кондратьева Е. И., Сорвачёва Т. Н. Оценка и коррекция нутритивного статуса у детей с муковисцидозом. Вопросы прак-тической педиатрии. 2018. Т. 13, № 5. С. 24–32
  295. Максимычева Т. Ю., Кондратьева Е. И., Сорвачёва Т. Н., Одинаева Н. Д. Опыт коррекции нутритивного статуса нутритивного статуса у детей с муковисцидозом с использованием компьютерных систем и средств сетевой коммуникации Сибирское медицинское обозрение. 2019. № 4. С. 67–73
  296. Prados C, Máiz L, Antelo C, Baranda F, Blázquez J, Borro JM, Gartner S, Garzón G, Girón R, de Gracia J, Lago J, Lama R, Martínez MT, Moreno A, Oliveira C, Pérez Frías J, Solé A, Salcedo A. [Cystic fibrosis: consensus on the treatment of pneumothorax and massive hemoptysis and on the indications for lung transplantation]. [Article in Spanish]  Arch Bronconeumol. 2000 Jul-Aug;36(7):411-6. DOI: 10.1016/s0300-2896(15)30141-1
  297. Hamilos D.L. Nasal and sinus problems in cystic fibrosis patients/ D.L. Hamilos // In: C. Bachert, A. Bourdin, P. Chanez, eds. The Nose and Sinuses in Respiratory Disorders (ERS Monograph). –  Sheffield: European Respiratory Society, 2017. –  C. 48–66 doi: 10.1183/2312508X.10009616
  298. Moss RB, King VV. Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage. Reduction in recurrence requiring surgery. Arch Otolaryngol Head Neck Surg. 1995; 121: 566-72
  299. Keck T, Rozsasi A. Medium-term symptom outcomes after paranasal sinus surgery in children and young adults with cystic fibrosis. Laryngoscope. 2007; 117: 475-9
  300. Liang J, Higgins TS, Ishman SL, Boss EF, Benke JR, Lin SY. Surgical management of chronic rhinosinusitis in cystic fibrosis: a systematic review. Int Forum Allergy Rhinol. 2013;3(10):814-22
  301. Boczar M, Sawicka E, Zybert K., Meconium ileus in newborns with cystic fibrosis - results of treatment in the group of patients operated on in the years 2000-2014. Dev Period Med. 2015 Jan-Mar;19(1):32-40
  302. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. / R. Yusen, L. Edwards, A. Dipchand [et al.]. - Текст : электронный // The Journal of Heart and Lung Transplantation. – 2016. – Vol. 35. – № 11. – P. 1170-1184.
  303. Репина С.А., Красовский С.А., Шмарина Г.В, Штаут М.И., Жекайте Е.К., Воронкова А.Ю., Шерман В.Д., Кондратьева Е.И., Черных В.Б. Состояние репродуктивной системы и алгоритм решения вопроса деторождения у мужчин с муковисцидозом // Альманах клинической медицины. 2019а. Т.47. №1. С.26-37. doi:10.18786/2072-0505-2019-47-001
  304. Edenborough FP, Borgo G, Knoop C et al. Guidelines for the management of pregnancy in women with cystic fibrosis. J Cyst Fibros. 2008 Jan;7 Suppl 1:S2-32. Epub 2007 Nov 19
  305. Pastro LDM, Lemos M, Fernandes FLA et al.  Longitudinal study of lung function in pregnant women: Influence of parity and smoking. Clinics (Sao Paulo). 2017 Oct; 72(10):595-599
  306. Gilljam M, Antoniou M, Shin J, Dupuis A, Corey M, Tullis DE. Pregnancy in cystic fibrosis.Fetal and maternal outcome. Chest. 2000 Jul;118(1):85-9
  307. Cheng EY, Goss CH, McKone EF. Aggressive prenatal care results in successful fetal outcomes in CF women.J Cyst Fibros. 2006 May; 5(2):85-91
  308. Odegaard I, Strayedersen B, Hallberg K, et al. Prevalence and outcome of pregnancies in Norwegian and Swedish women with cystic fibrosis. Acta Obstet Gynecol Scand 2002;81(8):693–7
  309. Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, Downer VS, Fliege J, Hazle LA, Jain M, Marshall BC, O"Malley C, Pattee SR, Potter-Bynoe G, Reid S, Robinson KA, Sabadosa KA, Schmidt HJ, Tullis E, Webber J, Weber DJ. Infect Control Hosp Epidemiol. 2014 Aug;35 Suppl 1:S1-S67. Epub 2014 Jul 1.PMID: 25025126 https://www.jstor.org/stable/pdf/10.1086/676882.pdf?refreqid=excelsior%3Ad2f3103ceec1d05c5a38a3b37dbf6f05
  310. Malfroot A., Adam G., Ciofu O., Döring G. et al. Immunisation in the current management of cystic fibrosis patients //Journal of Cystic Fibrosis. – 2005; 4(2):77-87
  311. Методические указания 3.3.1.1123-02 «Мониторинг поствакцинальных осложнений и их профилактика», части 9.6.5. Муковисцидоз, хронические воспалительные болезни легких. – Москва, 2002, – 44 с.
  312. Федеральное руководство по использованию лекарственных средств (формулярная система, справочное издание) Выпуск XVII. Под ред. А.Г. Чучалина, В.В. Яснецова В.В..  М.: ООО Видокс, 2016: 745-768
  313. Чучалин А.Г., Биличенко Т.И., Осипова Г.Л. и др. Вакцинопрофилактика болезней органов дыхания в рамках первичной медико-санитарной помощи населению. Клинические рекомендации. Пульмонология. 2015. 2(25): 1-19
  314. Костинов М.П. Руководство по клинической иммунологии в респираторной медицине / Под редакцией М.П. Костинова, А.Г. Чучалина, 2-е изд. – М.: Группа МДВ, 2018. – 304 с.
  315. Ежлова Е.Б. Эпидемиология и вакцинопрофилактика инфекции, вызываемой Streptococcus pneumoniae. Методические рекомендации / Е.Б. Ежлова и др. // Вакцинация. – 2011; 2:36-47
  316. Pneumococcal// GreenBook. – 2013; 25 (5): 295 – 314
  317. Kobayashi M., Bennett N.M., Gierke R., Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) // MMWR – 2015; 64 (34): 944 – 947
  318. Burgess L., Southern K. W. Pneumococcal vaccines for cystic fibrosis Cochrane Database Syst Rev. 2014 Aug 5;(8):CD008865
  319. Костинов М.П. Вакцинация взрослых с бронхолегочной патологией: Руководство для врачей / Под редакцией М.П. Костинова. – М.: Арт студия «Созвездие», 2013. – 112 с, 
  320. Рыжов А. А., Костинов М. П., Магаршак О. О. Применение вакцин против пневмококковой и гемофильной типа b инфекций у лиц с хронической патологией. Эпидемиология и вакцинопрофилактика, 2004;6 (19):24–27
  321. Ong E. L. Bilton D., Abbott J. et al. Influenza vaccination in adults with cystic fibrosis //BMJ: British Medical Journal. – 1991;303 (7):6557-6802
  322. Gross P. A., Denning C.R., Gaerlan P.F. et al. Annual influenza vaccination: immune response in patients over 10 years //Vaccine. – 1996; 14(13):1280-1284
  323. Poonam Dharmaraj, Rosalind L Smyth Vaccines for preventing influenza in people with cystic fibrosis Cochrane Database Syst Rev. 2014 Mar 6;2014(3):CD001753
  324. Эпидемиология и вакцинопрофилактика инфекции, вызываемой Haemophilus influenzae типа b. Методические рекомендации 3.3.1.0001 – 10//, М.: - 2010, с. 10
  325. Haemophilus influenzae type b (Hib) Vaccination Position Paper, weekly epidemiological record // WHO – 2013, 39 (88): 413 – 428
  326. Cerquetti M., Giufrè M. Why we need a vaccine for non-typeable Haemophilus influenzae //Human vaccines &immunotherapeutics. – 2016. – С. 1-5
  327. Баранов А.А., Брико Н.И., Горелов А.В. и др. Стратегии контроля ветряной оспы в России. Итоги Международного совещания Экспертного Совета по вопросам профилактики ветряной оспы (W.A.V.E) // Вопросы современной педиатрии, 2010. – Том 9. – №3. – С. 5–12,  // Вопросы современной педиатрии, 2010. – Том 9. – №3. – С. 5–12
  328. Баранов А.А., Намазова-Баранова Л.С., Таточенко В.К. Иммунопрофилактика менингококковой инфекции у детей (изд. 2-е, дополненное). Методические рекомендации / А.А. Баранов, Л.С. Намазова-Баранова, В.К. Таточенко, Е.А. Вишнёва, М.В. Федосеенко, Л.Р. Селимзянова, Ю.В. Лобзин, С.М. Харит, Н.И. Брико, М.П. Костинов, И.С. Королёва, Г.В. Белошицкий // М.: –Педиатр. – 2019. – 36 с.
  329. Баранов А.А., Намазова-Баранова Л.С., Таточенко В.К., Вакцинопрофилактика ротавирусной инфекции / клинические рекомендации // А.А. Баранов, Л.С. Намазова-Баранова, В.К. Таточенко, Е.А. Вишнёва, М.В. Федосеенко, Л.Р. Селимзянова, Ю.В. Лобзин, С.М. Харит, М.К. Бехтерева, Н.И. Брико,А.Я.  Миндлина, В.В. Кудрявцев, А.В. Горелов, А.Т. Подколзин, М.П. Костинов. – М.: 2017. – 24 с.
  330. Баранов А. А. и др. Клинические рекомендации по иммунопрофилактике респираторно-синцитиальной вирусной инфекции у детей // М. – 2016. – 16 С.
  331. Kua KP, Lee SWH. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis. Pharmacotherapy. 2017 Jun;37(6):755-769
  332. Bedossa, P., Poynard, T., and The METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996; 24: 289–293
  333. Морозов С.В., Труфанова Ю.М., Павлова Т.В. и др. Применение эластографии для определения выраженности фиброза печени: результаты регистрационного исследования в России. Эксп. клин. гастроэнтерол. 2008;2: 40–9
  334. C. Lemaitre, S. Dominique,  E. Billoud,  M. Eliezer,  H. Montialoux,  M. Quillard,  G. Riachi, E. Koning, H. Morisse-Pradier,  G. Savoye,  C. Savoye-Collet,  and O. Goria Relevance of 3D Cholangiography and Transient Elastography to Assess Cystic Fibrosis-Associated Liver Disease? Can Respir J. 2016; 2016: 4592702
  335. Christine K. Lee, Paul D. Mitchell, Roshan Raza, Sarah Harney, Shanna M. Wiggins, and Maureen M. Jonas Validation of Transient Elastography Cut-points to Assess Advanced Liver Fibrosis in Children and Young Adults: The Boston Children’s Hospital ExperienceJ Pediatr. 2018 Jul; 198: 84–89.e2
  336. Habib A., Bond W. M., Heuman D. M. Long-term management of cirrhosis: appropriate supportive care is both critical and difficult // Postgrad. Med. — 2001. — Vol. 109, № 3. — P. 101—113
  337. Клинические рекомендации. Остеопороз. под.ред. О.М. Лесняк, Л.И. Беневоленской. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2009. 272 с

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*